New England Surgical Society (NESS)
Search NESS
  Home
  Annual Meeting
  Annual Resident and Fellow Research Day
  Members
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Awards
  Journal of the American College of Surgeons
  Newsletters
  Committees
  Contact NESS

2010 Annual Meeting Abstracts

Back to Program


Preoperative treatment with infliximab is not associated with an increased risk of short-term postoperative complications after proctocolectomy with ileal pouch-anal anastomosis
*Melanie L. Gainsbury, *Daniel I Chu, *Lauren A. Howard, *Jennifer A. Coukos, *Jeremy T. Hetzel, *Francis A. Farraye, *Arthur F. Stucchi, James M. Becker
Boston University School of Medicine, Boston, MA

Objective: Considerable controversy exists over whether preoperative infliximab (IFX) use for ulcerative colitis (UC) increases the risk for short-term surgical complications after proctocolectomy with ileal pouch-anal anastomosis (IPAA). The aim of this study was to assess the association between preoperative IFX use in UC patients and short-term surgical complications following IPAA in a large single-surgeon cohort.
Design: Retrospective analysis of an IPAA registry.
Setting: Tertiary care academic referral center.
Patients: Ninety-two UC patients underwent IPAA at Boston University Medical Center from January 2005 through May 2009. Twenty-six patients treated with IFX within 12-weeks of their first-stage IPAA surgery were identified. Thirty-five control subjects were randomly selected from the remaining non-IFX group.
Interventions: No interventions.
Outcome: Short-term postoperative outcomes were compared between the two groups as defined by anastomotic leak, pelvic abscess, pouch-related, wound infection or ‘other’ complication occurring within 30 days of the loop ileostomy closure.
Results: Patients were similar with respect to age, gender, BMI, smoking status, ASA score, co-morbidities, rate of emergency surgery, handsewn anatomosis and preoperative use of methotrexate, cyclosporine, azathioprine, and medium- and high-dose steroids. IFX patients were more likely to have received a laparoscopic colectomy, 6-MP and low-dose steroids (<20 mg/day). There was no short-term mortality. Overall postoperative (65.4 vs. 74.3%, p=0.45) and infectious (35.7 vs. 60.9%, p=0.18) complications were similar between IFX and non-IFX groups. Multivariate regression models revealed no independent predictors for postoperative complications when including IFX (odds ratio 0.51, p=0.32), steroids, 6-MP, laparoscopic colectomy and BMI. Infliximab use was independently protective against wound infection (OR 9.5, p=0.03).
Conclusion: Preoperative IFX use was not associated with an increased risk of short-term postoperative complications after IPAA.


Back to Program

 

Copyright © 2018 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.